The following communications were distributed on the Registrants social media accounts on
November 12, 2020:
LinkedIn Post:
Urovant
Sciences (Nasdaq: UROV) has entered into a definitive agreement for Sumitovant Biopharma to acquire all outstanding shares of Urovant for $16.25 per share, or approximately $584 million in total equity value on a fully diluted basis, in an all-cash merger. The price represents a 96% premium over Urovants closing share price of $8.28 on November 12, 2020. The transaction is expected to close in the first quarter of 2021, subject to approval
by the minority shareholders. Important Information: https://ir.urovant.com/news-releases/news-release-details/urovant-sciences-enters-definitive-agreement-sumitovant
Twitter Feed:
Urovant Sciences (Nasdaq: UROV) has signed
a definitive agreement for Sumitovant Biopharma to acquire all outstanding shares of Urovant for $16.25 per share. Important Information:
https://ir.urovant.com/news-releases/news-release-details/urovant-sciences-enters-definitive-agreement-sumitovant
Additional Information and
Where to Find It
This communication is being made in respect of the proposed transaction involving Urovant and Sumitovant. Urovant intends to file
with the Securities and Exchange Commission (SEC) relevant materials, including a proxy statement on Schedule 14A in connection with the proposed transaction with Sumitovant, and Urovant and certain other persons, including Sumitovant,
intend to file a Schedule 13E-3 transaction statement with the SEC. The definitive proxy statement and Schedule 13E-3 transaction statement will be sent or given to the
shareholders of Urovant and will contain important information about the proposed transaction and related matters. UROVANTS SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION, THE SCHEDULE 13E-3 AND ANY OTHER RELEVANT DOCUMENTS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. The proxy statement, Schedule 13E-3 and other relevant materials (when they become available), and any other documents filed by Urovant with the SEC, may be obtained free of charge at the SECs website, at www.sec.gov. In addition,
securityholders of Urovant will be able to obtain free copies of the proxy statement and Schedule 13E-3 through the Investor Relations page of Urovants website, www.urovant.com, or by contacting
Urovants Investor Relations Department by mail at Attention: Investor Relations, 5281 California Ave, Suite #100, Irvine, CA 92617, or by telephone at (949) 769-2706.
Participants in the Solicitation
Urovant, its directors,
executive officers and other members of management and certain other persons may be deemed to be participants in the solicitation of proxies in connection with the proposed merger. Information about Urovants directors and executive officers is
included in Urovants Annual Report on Form 10-K for the year ended March 31, 2020 filed with the SEC on June 19, 2020, and the proxy statement for Urovants annual meeting of shareholders
for 2020, filed with the SEC on July 27, 2020.